Innovation Pharmaceuticals Inc (IPIX)

[TOB]

To clarify:

I think we over-estimate how much management knows. They've told us they're in the dark about trial details too -frrol

That reference was to the Brilacidin P2b when it was in progress and blinded. Not only to CTIX management, but to the trial investigators as well. They receive only very limited data while blinded which applies to the trial as a whole. They would not know which patients are receiving the Brilacidin or the Daptomycin while the trial was blinded.

The Kevetrin Phase 1 clinical trial is "open label." That means it is not blinded, there is no control or placebo group. The company and investigators receive all the data, and they know that all the patients are receiving Kevetrin.

Data CTIX would not have is not available yet, as a prime example, for the blood assays by qPCR for the P21 biomarkers for later cohorts. This because those tests have not been run. In this Dana Farber controls the scheduling, and last report is that "Hospital scientists are now running samples examining the effect of Kevetrin on p21 at higher dosing levels in more recent cohorts and Cellceutix hopes to disclose the results shortly."

There is however some protocol with release of data from an in-progress early stage open label trial, especially when the clinical trial is at a prestigious institution such as Dana Farber. Thus we hear only a couple tidbits from a couple of case studies, and this with lots of disclaimers about being only one, or a few cases.